NYSE: NVO
Novo Nordisk A S Earnings & Revenue

NVO past earnings growth

How has NVO's earnings growth performed historically?
Company
-12.12%
Industry
8.82%
Market
82.89%
NVO's earnings have grown slower (7.91% per year) than the US Biotechnology industry average (24.76%)
Performance
NVO's earnings have grown slower (7.91% per year) than the US market average (77.34%)
Performance
NVO's earnings growth is slowing down - its growth over the last year (-12.12%) is below its 5-year compound annual rate (7.91%)
Performance

NVO past revenue growth

How has NVO's revenue growth performed historically?
Company
-13.37%
Industry
199.31%
Market
16.55%
NVO's revenue has grown slower (5.02% per year) than the US Biotechnology industry average (85.68%)
Performance
NVO's revenue has grown slower (5.02% per year) than the US market average (15.67%)
Performance
NVO's revenue growth is slowing down - its growth over the last year (-13.37%) is below its 5-year compound annual rate (5.02%)
Performance

NVO earnings and revenue history

Current Revenue
$126.6B
Current Earnings
$41.4B
Current Profit Margin
32.70%

NVO Return on equity

Current Company
73.70%
Current Industry
7.00%
Current Market
-36.30%
NVO's Return on Equity (73.70%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

NVO Return on assets

Current Company
32.30%
Current Industry
-9.90%
Current Market
6.20%
NVO is generating higher Return on Assets (32.30%) than the US Biotechnology industry average (-11.12%)
Performance

NVO Return on capital employed

Current Company
80.02%
Current Industry
-1.60%
NVO's ability to generate Return on Capital (80.02%) has decreased compared to 3 years ago (94.73%)
Performance

Novo Nordisk A S Earnings & Revenue FAQ

On May 06, 2020, Novo Nordisk A S (NYSE: NVO) reported Q1 2020 earnings per share (EPS) of $5.07, up 16.02% year over year. Total Novo Nordisk A S earnings for the quarter were $11.90 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $4.37.
On May 06, 2020, Novo Nordisk A S (NYSE: NVO) reported Q1 2020 revenue of $33.88 billion up 15.65% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $29.29 billion.
As of Q4 2020, Novo Nordisk A S's earnings has grown -12.12% year over year. This is 20.94 percentage points lower than the US Biotechnology industry earnings growth rate of 8.82%. Novo Nordisk A S's earnings in the past year totalled $41.43 billion.
As of Q4 2020, Novo Nordisk A S's revenue has grown -13.37% year over year. This is 212.68 percentage points lower than the US Biotechnology industry revenue growth rate of 199.31%. Novo Nordisk A S's revenue in the past year totalled $126.58 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics